GRK5 and cancer: Furthermore, we observed that treatment with the multispecific kinase inhibitor sunitinib decreases the cancer cell migration by reducing the GRK5 expression levels resulting in attenuated GRPR signalling, depicting a novel mechanism of action of a well-known drug.